Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 13/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101487 | 0.90 | ACVRL1 (0.35) | ACVRL1PIK3CDADORA2API4KAPI4K2B | |
| SCHEMBL10101498 | 0.89 | ACVRL1 (0.37) | ACVRL1PIK3CD | |
| SCHEMBL10101501 | 0.88 | PIK3CD (0.38) | ACVRL1PIK3CD | |
| SCHEMBL10101517 | 0.85 | CSNK2A2 (0.33) | ACVRL1PIK3CD | |
| SCHEMBL10101522 | 0.85 | ACVRL1 (0.32) | ACVRL1ADORA2A | |
| SCHEMBL10101509 | 0.85 | PIK3CD (0.36) | ACVRL1PIK3CD | |
| SCHEMBL10101521 | 0.85 | NPC1 (0.35) | ACVRL1PIK3CDADORA2A | |
| SCHEMBL10101547 | 0.85 | ADK (0.35) | ACVRL1PIK3CDADORA2A | |
| SCHEMBL10101492 | 0.84 | ACVRL1 (0.34) | ACVRL1PIK3CDADORA2API4KAPI4K2B | |
| SCHEMBL10101542 | 0.84 | ACVRL1 (0.32) | ACVRL1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119607-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-21 | — | — | US | disclosed |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | ACVRL1 4215/4885PIK3CD 636/4885ADORA2A 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.